Skip to main content

Table 3 Sites of clinically suspected infections and use of antibiotics at baseline (safety population)

From: A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock

  AZD9773 cohort 1
(50 U/kg)
(n= 8)
AZD9773 cohort 2
(250 U/kg)
(n= 9)
AZD9773 cohort 3
(250/50 U/kg) (n= 12)
AZD9773 cohort 4
(500/100 U/kg) (n= 10)
AZD9773 cohort 5
(750/250 U/kg)
(n= 8)
Placebo (n= 23) Total
(n= 70)
Infection site, n (%)
   Abdomen 2 (25.0) 3 (33.3) 2 (16.7) 1 (10.0) 5 (62.5) 3 (13.0) 16 (22.9)
   Catheter/device 1 (12.5) 0 0 0 0 0 1 (1.4)
   Lung 3 (37.5) 4 (44.4) 6 (50.0) 6 (60.0) 2 (25.0) 12 (52.2) 33 (47.1)
   Skin and soft tissue 1 (12.5) 1 (11.1) 1 (8.3) 1 (10.0) 0 4 (17.4) 8 (11.4)
   Unknown 1 (12.5) 1 (11.1) 2 (16.7) 2 (20.0) 0 1 (4.3) 7 (10.0)
   Urinary tract 0 0 3 (25.0) 0 1 (12.5) 3 (13.0) 7 (10.0)
Time from qualifying organ failure to first antibiotic use, hours*
  ( n = 7) ( n = 6) ( n = 9) ( n = 7) ( n = 8) ( n = 19) ( n = 56)
Median
(range)
-4.4
(-39.0 to 20.6)
-10.1
(-85.7 to 0.7)
-0.8
(-41.3 to 16.4)
-3.9
(-108.2 to 1.2)
-6.3
(-85.1 to 6.5)
-4.9
(-366.5 to 12.8)
-4.2
(-366.5 to 20.6)
  1. *A negative time indicates that antibiotics were given before qualifying organ failure